ERBB2 and cancer: A total of 62 patients with HER2-negative cancer received first-line fluoropyrimidine/platinum chemotherapy (capecitabine /oxaliplatin (n = 45), 5-fluorouracil (5-FU)/oxaliplatin and leucovorin (n = 13), S-1/cisplatin (n = 2), and capecitabine/cisplatin (n = 2)) and six patients with HER2-positive cancer received trastuzumab and capecitabine/cisplatin (n = 4) or 5-FU/cisplatin (n = 2).